Quarterly report · Q1
7459.TEDINET S100OYEC
Period2022-04-01 → 2022-06-30
Filed2022-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 34
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥838.3bn | 2022-04-01 → 2022-06-30 | Cons. | Net sales |
| Revenue | ¥3.29T | 2021-04-01 → 2022-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥824.9bn | 2021-04-01 → 2021-06-30 | Cons. | Net sales |
| Operating income | ¥13.5bn | 2022-04-01 → 2022-06-30 | Cons. | Operating income |
| Operating income | ¥13.3bn | 2021-04-01 → 2021-06-30 | Cons. | Operating income |
| Ordinary income | ¥17.6bn | 2022-04-01 → 2022-06-30 | Cons. | Ordinary income |
| Ordinary income | ¥62.0bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.4bn | 2021-04-01 → 2021-06-30 | Cons. | Ordinary income |
| Profit before tax | ¥17.2bn | 2022-04-01 → 2022-06-30 | Cons. | Income before income taxes |
| Profit before tax | ¥17.5bn | 2021-04-01 → 2021-06-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥8.3bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥29.4bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥9.4bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥10.8bn | 2022-04-01 → 2022-06-30 | Cons. | Profit loss |
| Net income | ¥12.2bn | 2021-04-01 → 2021-06-30 | Cons. | Profit loss |
| Total assets | ¥1.72T | at 2022-06-30 | Cons. | Assets |
| Total assets | ¥1.71T | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.70T | at 2021-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.06T | at 2022-06-30 | Cons. | Liabilities |
| Total liabilities | ¥1.06T | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥659.0bn | at 2022-06-30 | Cons. | Net assets |
| Net assets / equity | ¥649.1bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥645.5bn | at 2021-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥218.8bn | at 2022-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥243.2bn | at 2022-03-31 | Cons. | Cash and deposits |
| EPS (basic) | ¥39.39 | 2022-04-01 → 2022-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥140.14 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥44.99 | 2021-04-01 → 2021-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥36.94 | 2022-04-01 → 2022-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥131.41 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥42.22 | 2021-04-01 → 2021-06-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 31.4% | at 2022-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.0% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.1% | at 2021-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 38
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-06-30 | −¥913m |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-06-30 | −¥913m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-06-30 | ¥98m |
| jpcrp040300-q1r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥18.5bn |
| jpcrp040300-q1r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥18.5bn |
| jpcrp040300-q1r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥1m |
| jpcrp040300-q1r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥692m |
| jpcrp040300-q1r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥276.2bn |
| jpcrp040300-q1r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥276.2bn |
| jpcrp040300-q1r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥94m |
| jpcrp040300-q1r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥6.5bn |
| jpcrp040300-q1r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2022-04-01 → 2022-06-30 | ¥544.4bn |
| jpcrp040300-q1r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2022-04-01 → 2022-06-30 | ¥543.6bn |
| jpcrp040300-q1r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥817m |
| jpcrp040300-q1r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2022-04-01 → 2022-06-30 | ¥6.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-06-30 | ¥839.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-06-30 | ¥838.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-06-30 | ¥913m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-06-30 | ¥13.4bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2021-06-30 | −¥937m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2021-06-30 | −¥937m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2021-06-30 | ¥169m |
| jpcrp040300-q1r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥18.1bn |
| jpcrp040300-q1r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥18.1bn |
| jpcrp040300-q1r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥0 |
| jpcrp040300-q1r_E02632-000Animal Health Products And Food Processing Raw Materials Wholesale Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥734m |
| jpcrp040300-q1r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥269.7bn |
| jpcrp040300-q1r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥269.6bn |
| jpcrp040300-q1r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥90m |
| jpcrp040300-q1r_E02632-000Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥7.0bn |
| jpcrp040300-q1r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2021-04-01 → 2021-06-30 | ¥538.0bn |
| jpcrp040300-q1r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2021-04-01 → 2021-06-30 | ¥537.1bn |
| jpcrp040300-q1r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥846m |
| jpcrp040300-q1r_E02632-000Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2021-04-01 → 2021-06-30 | ¥5.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2021-06-30 | ¥825.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2021-06-30 | ¥824.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2021-06-30 | ¥937m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2021-06-30 | ¥13.1bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 379
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)有限責任 あずさ監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)塚原 克哲 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)御厨 健太郎 | |
| Cpa3 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)木村 純一 | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior1YTDDuration | 824877000000 | JPY |
| Net sales (5-year summary) | CurrentYTDDuration | 838328000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 3290921000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YTDDuration | 17362000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYTDDuration | 17586000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 62046000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YTDDuration | 9445000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYTDDuration | 8270000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 29423000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YTDDuration | 12606000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYTDDuration | 15968000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 25291000000 | JPY |
| Net assets (5-year summary) | Prior1QuarterInstant | 645530000000 | JPY |
| Net assets (5-year summary) | CurrentQuarterInstant | 659040000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 649089000000 | JPY |
| Total assets (5-year summary) | Prior1QuarterInstant | 1697649000000 | JPY |
| Total assets (5-year summary) | CurrentQuarterInstant | 1717354000000 | JPY |
| Total assets (5-year summary) | Prior1YearInstant | 1709474000000 | JPY |
| Basic earnings loss per share (5-year summary) | Prior1YTDDuration | 44.99 | |
| Basic earnings loss per share (5-year summary) | CurrentYTDDuration | 39.39 | |
| Basic earnings loss per share (5-year summary) | Prior1YearDuration | 140.14 | |
| Diluted earnings per share (5-year summary) | Prior1YTDDuration | 42.22 | |
| Diluted earnings per share (5-year summary) | CurrentYTDDuration | 36.94 | |
| Diluted earnings per share (5-year summary) | Prior1YearDuration | 131.41 | |
| Equity to asset ratio (5-year summary) | Prior1QuarterInstant | 0.311 | |
| Equity to asset ratio (5-year summary) | CurrentQuarterInstant | 0.314 | |
| Equity to asset ratio (5-year summary) | Prior1YearInstant | 0.310 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 244524496 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 244524496 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 244524496 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 244524496 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 34562200 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 209771500 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 2097715 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 190796 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 244524496 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 2097715 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 34562200 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 34562200 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |